In November 2022, the EU Innovation Network (EU IN) has launched phase 2b of the Simultaneous National Scientific Advice (SNSA) pilot. Phase 2b of the SNSA pilot will run until the end of 2024.
SNSA is intended to be used in situations where an applicant wishes to obtain national scientific advice from two National Competent Authorities (NCA) at the same time.
The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products participates in phase 2b of the SNSA. The list of participating NCA’s and contact info, guidance to applicants and an application form are attached below.
More information on the SNSA is available on the Heads of Medicines Agencies (HMA) website: https://www.hma.eu/about-hma/working-groups/eu-innovation-network-eu-in.html
For any further information, please contact SNSA@pei.de
Details of how the SNSA procedure will proceed at national level will be published after the completion of legislative work involving an amendment to the law with regard to the competence of the President of the Office on the issue of scientific advice.
